Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-30T19:33:36.589Z Has data issue: false hasContentIssue false
  • English
  • Français

Switching from SSRIs to Nefazodone: Three Case Reports

Published online by Cambridge University Press:  07 November 2014

Norman Sussman ,
Ricardo Castaneda  and
Robert Levy
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Grand Rounds—Case Reports
Information
CNS Spectrums , Volume 2 , Issue 4: Schizophrenia & OCD: Divergence , April 1997 , pp. 56 - 62
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Preskorn, SH.Comparison of the tolerability of nefazodone, imipramine, fluoxetine, sertraline, paroxetine, and venlafaxine. J Clin Psychiatry. 1995;56(suppl 6):12–21.Google ScholarPubMed
2.Castaneda, R, Levy, R, Westreich, L, Sussman, N. Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents (Letter). J Clin Psychiatry. 1996:57:485–486.Google Scholar
3.Benjamin, J, Greenberg, BD, Murphy, DL. Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects. Psycho-pharmacology. 1996;127:140–149.CrossRefGoogle ScholarPubMed
4.Germine, M, Goddard, AW, Sholomskas DE, Woods SW, Charney DS, Henninger GR. Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res. 1994;54:115–133.CrossRefGoogle Scholar
5.Germine, M, Goddard, AW, Woods, SW, Charney, DS, Henninger, GR. Anger and anxiety responses to mchlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry. 1992;32:457–461.CrossRefGoogle ScholarPubMed
6.Charney, DS, Woods, SW, Goodman, WK, Henninger, GR. Serotonin function in anxiety. II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology. 1987;92:14–24.CrossRefGoogle ScholarPubMed
7.Pigott, TA, Hill, JL, Grady, TA, et al.A comparison of the behavioral effects of oral versus intravenous m-CPP administration in OCD patients and the effects of metergoline prior to IVmCPP. Biol Psychiatry. 1993;33:3–14.CrossRefGoogle Scholar
8.Stein, DJ, Hollander, E, DeCaria, CM, Simeon, D, Cohen, L, Aronowitz, B. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures. Biol Psychiatry. 1996;40:508–513.CrossRefGoogle ScholarPubMed
9.Krystal, JH, Webb, E, Cooney, N, Kranzler, HR, Charney, DS. Specifity of ethanol-like effects elicited by serotonergic and noradrenergic mechanisms. Arch Gen Psychiatry. 1994;51:898–911.CrossRefGoogle Scholar
10.Walsh, AE, Hockney, RA, Campling, G, Cowen, PJ. Neuroendocrine and temperature effects of nefazodone in healthy volunteers. Biol Psychiatry. 1993;33:115–119.CrossRefGoogle ScholarPubMed
11.Bonson, KR, Buckholtz, JW, Murphy, DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsycho-pharmacology. 1996;14:425–436.CrossRefGoogle ScholarPubMed
12.Kahn, RS, Davidson, M, Siever, LJ, Sevy, S, Davis, KL. Clozapine treatment and its effect on neuroendocrine responses induced by the serotonergic agonist m-chlorophenylpiperazine. Biol Psychiatry. 1994;35: 909–912.CrossRefGoogle Scholar
13.Laakso, A, Palvimaki, E-P, Kuoppamaki, M, Syvalahti, E, Hietala, J. Chronic citalopram and fluoxetine treatments upregulate 5-HT2C receptors in the rat choroid plexus. Neuropsychopharmacology. 1996;15:143–151.CrossRefGoogle ScholarPubMed
14.Palvimaki, E-P, Roth, BL, Majasuo, H, et al. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor. Psychopharmacology. 1996:126: 234–240.CrossRefGoogle ScholarPubMed
15.Wong, DT, Threlkeld, PG, Robertson, DW. Affinities of fluoxetine, its enanthomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology. 1991;5:43–47.Google ScholarPubMed
16.Maj, J, Bijak, M, Dziedzicka-Wasylewska, M, et al.The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology. 1996;127:78–82.CrossRefGoogle ScholarPubMed
17.Hollander, E, Decaria, CM, Gulley, R, et al.Effects of chronic fluoxetine on behavioral and neuroendocrine response to meta-chlorophenyldiperazine in obsessive-compulsive disorder. Psychiatry Res. 1991;36:1–17.CrossRefGoogle ScholarPubMed
18.Barbhaiya, RH, Shukla, UA, Natarajan, CS, Behr, DA, Greene, DS, Sainati, SM. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clin Pharmacol Therapeut. 1995;58:390–398.CrossRefGoogle ScholarPubMed
19.Tecott, LH, Sun, LM, Akana, SF, et al.Eating disorders and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature. 1995;374:542–546.CrossRefGoogle ScholarPubMed
20.Pigott, TA, Zohar, J, Hill, JL, et al.Metergoline blocks the behavioral and norendocrine effects of orally administered meta-chlorophenyldiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991;29:418–426.CrossRefGoogle ScholarPubMed